iSAM Funds UK Ltd Reduces Stake in STERIS plc $STE

iSAM Funds UK Ltd cut its position in shares of STERIS plc (NYSE:STE) by 35.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,466 shares of the medical equipment provider’s stock after selling 2,967 shares during the quarter. iSAM Funds UK Ltd’s holdings in STERIS were worth $1,353,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of STE. Steigerwald Gordon & Koch Inc. acquired a new stake in STERIS in the third quarter valued at $25,000. Cloud Capital Management LLC acquired a new position in shares of STERIS during the 3rd quarter worth $29,000. Geneos Wealth Management Inc. raised its stake in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares during the last quarter. TruNorth Capital Management LLC purchased a new stake in shares of STERIS in the 3rd quarter worth about $37,000. Finally, Root Financial Partners LLC acquired a new stake in STERIS in the 3rd quarter valued at about $39,000. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at STERIS

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director directly owned 705 shares in the company, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.07% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

STE has been the topic of several recent research reports. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $275.20.

STERIS Stock Performance

NYSE STE opened at $214.66 on Friday. The business’s 50-day moving average price is $250.96 and its 200 day moving average price is $250.50. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. STERIS plc has a twelve month low of $204.90 and a twelve month high of $269.44. The company has a market capitalization of $21.05 billion, a PE ratio of 29.94 and a beta of 1.05.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same period last year, the firm posted $2.32 EPS. The business’s revenue for the quarter was up 9.2% compared to the same quarter last year. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, research analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS’s payout ratio is 35.15%.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.